OraSure Technologies Expands Distribution of Over-the-Counter Cryosurgical Wart Removal Product in Latin America
04 3์ 2008 - 8:00PM
Business Wire
OraSure Technologies, Inc. (NASDAQ:OSUR) announced today the
execution of new agreements to expand distribution of OraSure๏ฟฝs
cryosurgical wart removal product by Genomma Lab in the
over-the-counter (๏ฟฝOTC๏ฟฝ) or consumer retail market in Central and
South America. In addition, the parties renewed and extended their
prior distribution arrangement for Mexico and signed a new
agreement to distribute the product in South Africa. Under the
agreements, the product will be manufactured by OraSure and sold
under the POINTTS tradename by the Genomma Lab affiliates of
Producciones Infovision, S.A. de C.V. to pharmacies and retailers
in Mexico, Brazil, Argentina, a number of other Central and South
American countries, and South Africa. ๏ฟฝWe are pleased to expand our
collaboration with Genomma Lab to make our cryosurgical wart
removal product widely available to the consumer markets in Latin
America,๏ฟฝ said Douglas A. Michels, President and CEO of OraSure
Technologies. ๏ฟฝOur initial launch in Mexico was extremely
successful and set the stage for a broader relationship. We believe
Central and South America represent an important opportunity to
expand our OTC cryosurgical business significantly in the
international marketplace.๏ฟฝ ๏ฟฝThere is a large market demand for an
over-the-counter cryosurgical wart removal product in Central and
South America, and we are thrilled to be able to incorporate the
POINTTS product into our extensive line of personal care products
to help meet this need,๏ฟฝ said Rodrigo Herrera Aspra, Genomma Lab
President. ๏ฟฝWe look forward to a successful collaboration with
OraSure Technologies.๏ฟฝ The POINTTS wart removal product consists of
a small aerosol canister containing a refrigerant, and a package of
12 foam buds attached to hollow tube applicators. In order to treat
a common or plantar wart, the foam bud applicator is inserted into
the nozzle of the canister, refrigerant is dispensed in order to
freeze the foam bud and the bud is then applied to the affected
area. About OraSure Technologies In addition to cryosurgical
products which are sold in both the professional and consumer
markets, OraSure Technologies develops, manufactures and markets
oral fluid specimen collection devices using proprietary oral fluid
technologies, diagnostic products including immunoassays and other
in vitro diagnostic tests. These products are sold in the United
States as well as internationally to various clinical laboratories,
hospitals, clinics, community-based organizations and other public
health organizations, distributors, government agencies,
physicians๏ฟฝ offices, and commercial and industrial entities.
OraSure Technologies is the leading supplier of oral fluid
collection devices and assays to the life insurance industry and
public health markets for the detection of antibodies to HIV. In
addition, the Company supplies oral fluid testing solutions for
drugs of abuse testing. For more information on the Company, please
go to www.orasure.com. About Producciones Infovision Producciones
Infovision is a leading industrial group in Mexico with interests
in manufacturing, distribution, retail and television production.
Genomma Lab is a wholly-owned subsidiary of Producciones Infovision
that develops, makes and commercializes pharmaceutical, and
cosmetic products. For more information on Producciones Infovision
and Genomma Lab, please go to www.genommalab.com. Important
Information This press release contains certain forward-looking
statements, including with respect to product sales, launches and
markets. Actual results could be significantly different. Factors
that could affect results include the ability to market and sell
products; changes in relationships, including disputes or
disagreements, with strategic partners and reliance on strategic
partners for the performance of critical activities under
collaborative arrangements; failure of distributors or other
customers to meet purchase forecasts or minimum purchase
requirements for the Company๏ฟฝs products; impact of competitors,
competing products and technology changes; ability to develop,
commercialize and market new products; market acceptance of oral
fluid testing or other products; changes in market acceptance of
products based on product performance; continued bulk purchases by
customers, including governmental agencies, and the ability to
fully deploy those purchases in a timely manner; ability to fund
research and development and other products and operations; ability
to obtain and maintain new or existing product distribution
channels; reliance on sole supply sources for critical product
components; availability of related products produced by third
parties or products required for use of our products; ability to
obtain, and timing and cost of obtaining, necessary regulatory
approvals for new products or new indications or applications for
existing products; ability to comply with applicable regulatory
requirements; history of losses and ability to achieve sustained
profitability; volatility of our stock price; uncertainty relating
to patent protection; uncertainty and costs of litigation relating
to patents and other intellectual property; availability of
licenses to patents or other technology; ability to enter into
international manufacturing agreements; obstacles to international
marketing and manufacturing of products; ability to sell products
internationally; loss or impairment of sources of capital; ability
to meet financial covenants in agreements with financial
institutions; ability to retain qualified personnel; exposure to
patent infringement, product liability and other types of
litigation; changes in international, federal or state laws and
regulations; customer consolidations and inventory practices;
equipment failures and ability to obtain needed raw materials and
components; the impact of terrorist attacks and civil unrest;
ability to complete consolidation or restructuring activities;
ability to identify, complete and realize the full benefits of
potential acquisitions; and general political, business and
economic conditions. These and other factors are discussed more
fully in the Securities and Exchange Commission (๏ฟฝSEC๏ฟฝ) filings of
OraSure Technologies, including its registration statements, its
Annual Report on Form 10-K for the year ended December 31, 2006,
its Quarterly Reports on Form 10-Q, and its other filings with the
SEC. Although forward-looking statements help to provide complete
information about future prospects, readers should keep in mind
that forward-looking statements may not be reliable. OraSure
Technologies undertakes no duty to update any forward-looking
statements after they are made.
OraSure Technologies (NASDAQ:OSUR)
๊ณผ๊ฑฐ ๋ฐ์ดํฐ ์ฃผ์ ์ฐจํธ
๋ถํฐ 6์(6) 2024 ์ผ๋ก 7์(7) 2024
OraSure Technologies (NASDAQ:OSUR)
๊ณผ๊ฑฐ ๋ฐ์ดํฐ ์ฃผ์ ์ฐจํธ
๋ถํฐ 7์(7) 2023 ์ผ๋ก 7์(7) 2024